Inbiobank is a non profit-making bank of stem and primary cells the function of which is to produce and characterise such cells for their use in applied research, both basic and clinical.
Inbiobank’s installations have technologically pioneering, state-of-the-art equipment. Its cell production plant has ISO 9001- 2000 quality certification and it works in and operates with GMP (Good Manufacturing Practices) conditions, thus guaranteeing the clinical quality of the cells produced. Moreover, these installations have been authorised as pharmaceutical laboratories (Nº 4206 E) by the Spanish Medication Agency to carry out clinical trials (PEI 05-057) using somatic cell therapy, only the second throughout Spain with such authorisation.
About adult stem cells
Adult stem cells are responsible for cellular and tissue regeneration and are located in various tissues of the body. Generally these are extracted from easily-accessible tissues with high capacity for renovation, such as bone marrow, skin, intestine and fatty tissue.
Thanks to their potential therapeutic and regenerative activity, adult stem cells provide multiple possibilities for the treatment of many pathologies. Moreover, given their adult origin, they are free of the legal and ethical problems associated with stem cells originating from other sources.
Basic research at Inbiomed
Currently, Inbiomed is working on three main lines of basic research, all based on the study of adult stem cells of human origin and that come from a number of different tissues:
· bone marrow, umbilical cord and adipose tissue stem cells
· skin stem cells
· neuronal stem cells
Within these lines of research, Inbiomed is studying the mechanisms, both genetic and biochemical, that intervene in the multiplication and differentiation of these cells in the various body tissues as well as in their biological function. The quest is also to find ways of reconstituting in vitro the environment in which these adult stem cells multiply and differentiate.
Clinical research at Inbiomed
The Inbiomed Foundation is participating, together with the Spanish Consortium for Epidermolisis Bullosa in clinical trials (PEI 05- 057) the aim of which is to test the efficacy and safety of a new treatment for Epidermolisis Bullosa, and based on the use of engineered chimeric bilaminar skin (produced artificially in the pharmaceutical laboratory), and compare it with a current commercial treatment.
Irati Kortabitarte | alfa
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences